

## Curriculum Vitae

Personal information **Niklas Walther**

### Work experience

---

1. Employer: Paul Ehrlich Institut

- Start date: 05/2023
- End date: current
- Position: Clinical assessor
- Activities:
- Country: Germany

2. Employer: Charite Research Organisation

- Start date: 08/2018
- End date: 09/2022
- Position: Study physician
- Activities:
- Country: Germany

3. Employer: Accenture, Healthcare Consulting Services & Solutions

- Start date: 08/2017
- End date: 06/2018
- Position: Junior Consultant
- Activities:
- Country: Austria

### Education and training

---

Institution: University of Düsseldorf

Start Date: 10/2010

End Date: 07/2017

Degree: MD

Subjects: Human medicine

Country: Germany

### Additional information

---

#### Publications

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin compared with Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind Study Diabetes Care · Jul 11, 2022 o Hemoglobin Rothschild – Unimpaired physical performance and oxygen uptake – A case report with literature review Hemoglobin Rothschild – Unimpaired physical performance and oxygen uptake – A case report with literature review Respiratory Medicine Case Reports · Jun 3, 2022 o Lu, P., Lesage, A., Crabbé, R., Groen, K., Gibson, C., Walther, N., & Knolle, J. (2020). P152 PHA-022121, A SELECTIVE BRADYKININ-B2-RECEPTOR ANTAGONIST, IS SAFE AND SHOWS RAPID ORAL BIOAVAILABILITY IN HUMANS. Annals of Allergy, Asthma & Immunology, 125(5), Supplement, S21-S22. <https://doi.org/10.1016/j.anai.2020.08.085> o [Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: A three-part randomized, double-blind, placebo-controlled trial](#) Walther N, Schultz-Heienbrock R, Staß H, Corman VM, Gassen NC, et al. (2025) Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: A three-part randomized, double-blind, placebo-controlled trial. PLOS ONE 20(2): e0303924.

#### Projects

Memberships

Other Relevant Information